去勢抗性之轉移性前列腺癌病患接受abiraterone acetate之療效及安全性短期報告
洪啟峰、楊晨洸、歐宴泉、賀昊中、程千里、裘坤元、蘇重光、
王賢祥、陳卷書、李建儀、陳正哲
臺中榮民總醫院 外科部 泌尿外科
The short-term efficacy and safety of abiraterone acetate with prednisone in metastatic castration-resistant prostate cancer patients in VGHTC
Chi-Feng Hung, Cheng-Kuang Yang, Yen-ChuanOu, Hao-Chung Ho, Chen-Li Cheng, Kun-Yuan Chiu, Chung-Kuang Su, Shian-Shiang Wang, Chuan-Shu Chen, Jian-Ri Li, Cheng-Che Chen.
Divisions of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
Purpose: To report short-term efficacy and safety of abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer patients in VGHTC.
Materials and Methods: A total of 25 patients with metastatic castration-resistant prostate cancer who have progressive disease or have become intolerance while receiving docetaxel were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen (PSA) reduction ≥ 50% were considered as PSA response, as COU-AA301 definition.
Results: There were 14 patients (56%) achieving PSA response, 6 (24 %) having stable disease, and five (20 %) PSA progression, respectively. The most common adverse event was hypokalemia (12%) and liver function abnormalities (12 %). But hyperkalemia developed in two patients (8%). Grade 3/4 adverse event was observed in one patient (4%).
Conclusions: Abiraterone acetate with prednisolone is potentially a favorable treatment in patients with metastatic castration-resistant prostate cancer after treatment failure with docetaxel-based chemotherapy.